Evidence map›Paper›PMID 37714251›Full record

ArticleArchives of biochemistry and biophysics2023

Cooperative & competitive binding of anti-myosin tail antibodies revealed by super-resolution microscopy.

Dua'a Quedan, Rohit Singh, Amal Akel, Andrea L Bernardino, Christopher Thang, Mithilesh Bhaskaruni, Anushka Haldankar, Bertrand C W Tanner, Douglas D Root

Open access · greenAbstract read
In one paragraph

Article in Archives of biochemistry and biophysics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Dua'a QuedanDepartment of Biological Sciences, Division of Biochemistry and Molecular Biology, University of North Texas, Denton, TX, 76203, USA.
Rohit SinghDepartment of Biological Sciences, Division of Biochemistry and Molecular Biology, University of North Texas, Denton, TX, 76203, USA.
Amal AkelDepartment of Biological Sciences, Division of Biochemistry and Molecular Biology, University of North Texas, Denton, TX, 76203, USA.
Andrea L BernardinoDepartment of Biological Sciences, Division of Biochemistry and Molecular Biology, University of North Texas, Denton, TX, 76203, USA.
Christopher ThangDepartment of Biological Sciences, Division of Biochemistry and Molecular Biology, University of North Texas, Denton, TX, 76203, USA.
Mithilesh BhaskaruniDepartment of Biological Sciences, Division of Biochemistry and Molecular Biology, University of North Texas, Denton, TX, 76203, USA.
Anushka HaldankarDepartment of Biological Sciences, Division of Biochemistry and Molecular Biology, University of North Texas, Denton, TX, 76203, USA.
Bertrand C W TannerDepartment of Integrative Physiology & Neuroscience, Washington State University, Pullman, WA, 99164, USA.
Douglas D RootDepartment of Biological Sciences, Division of Biochemistry and Molecular Biology, University of North Texas, Denton, TX, 76203, USA. Electronic address: droot@unt.edu.
University of North Texas · USWashington State University · US

Funding

Length-dependent activation in human myocardiumR01HL149164 · NHLBI · UNIVERSITY OF KENTUCKY · PI CAMPBELL, KENNETH S, TANNER, BERTRAND C.W. · 2020 to 2023
$2.8M
NHLBI NIH HHS R01 HL149164
6 · The paper itself

Abstract

The MF30 monoclonal antibody, which binds to the myosin subfragment-2 (S2), was found to increase the extent of myofibril shortening. Yet, previous observations found no effect of this antibody on actin sliding over myosin during in vitro motility assays with purified proteins in which myosin binding protein C (MyBPC) was absent. MF30 is hypothesized to enhance the availability of myosin heads (subfragment-1 or S1) to bind actin by destabilizing the myosin S2 coiled-coil and sterically blocking S2 from binding S1. The mechanism of action likely includes MF30's substantial size, thereby inhibiting S1 heads and MyBPC from binding S2. Hypothetically, MF30 should enhance the ON state of myosin, thereby increasing muscle contraction. Our findings indicate that MF30 binds preferentially to the unfolded heavy chains of S2, displaying positive cooperativity. However, the dose-response curve of MF30's enhancement of myofibril shortening did not suggest complex interactions with S2. Single, double, and triple-stained myofibrils with increasing amounts of antibodies against myosin rods indicate a possible competition with MyBPC. Additional assays revealed decreased fluorescence intensity at the C-zone (central zone in the sarcomere, where MyBPC is located), where MyBPC may inhibit MF30 binding. Another monoclonal antibody named MF20, which binds to the light meromyosin (LMM) without affecting myofibril contraction, showed less reduction in fluorescence intensity at the C-zone in expansion microscopy than MF30. Expansion microscopy images of myofibrils labeled with MF20 revealed labeling of the A-band (anisotropic band) and a slight reduction in the labeling at the C-zone. The staining pattern obtained from the expansion microscopy image was consistent with images from photolocalization microscopy which required the synthesis of unique photoactivatable quantum dots, and Zeiss Airyscan imaging as well as alternative expansion microscopy digestion methods. Consistent with the hypothesis that MF30 competes with MyBPC binding to S2, cardiac tissue from MyBPC knockout mice was stained more intensely, especially in the C-zone, by MF30 compared to the wild type.

Indexed as

ActinsMicroscopyAnimalsAntibodies, MonoclonalBinding, CompetitiveMiceMyosinsMyosin SubfragmentsActinsAntibodies, MonoclonalMyosinsMyosin SubfragmentsExpansion microscopyMF30MyBPCMyofibrilMyosin Sub-fragment 2Photolocalization

Identifiers

PMID37714251
PMCPMC12258078
OpenAlexW4386701324

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.